Stirling Bryan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient outcomes, according to new research from the University of British Columbia. The study, published today in <a href="https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221785"><em>CMAJ</em></a>, shows that in B.C. alone, implementing pharmacogenomic testing could save the provincial public health system an estimated $956 million over 20 years.</p>

VANCOUVER - Loss. That's the word that comes to mind when Linda Riches thinks of the debilitating depression that robbed her of the ability to fully care for her son, advance in her career and pursue her goal of a PhD in education.

VANCOUVER — Loss. That's the word that comes to mind when Linda Riches thinks of the debilitating depression that robbed her of the ability to fully care for her son, advance in her career and pursue her goal of a PhD in education.

A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient outcomes, according to new research from the University of British Columbia.

Matching Canadians with right anti-depressants through pharmacogenomic testing could also save lives